APA (7th ed.) Citation

EE, D., GI, S., AR, P., ML, J., AW, T., JA, T., . . . AM, S. (2026). Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors. The New England journal of medicine, 394(9), 872. https://doi.org/10.1056/NEJMoa2508820

Chicago Style (17th ed.) Citation

EE, Dumbrava, et al. "Phase 1 Study of Rezatapopt, a P53 Reactivator, in TP53 Y220C-Mutated Tumors." The New England Journal of Medicine 394, no. 9 (2026): 872. https://doi.org/10.1056/NEJMoa2508820.

MLA (9th ed.) Citation

EE, Dumbrava, et al. "Phase 1 Study of Rezatapopt, a P53 Reactivator, in TP53 Y220C-Mutated Tumors." The New England Journal of Medicine, vol. 394, no. 9, 2026, p. 872, https://doi.org/10.1056/NEJMoa2508820.